

AD HOC ANNOUNCEMENT

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

Alzchem Group AG

Dr.-Albert-Frank-Str. 32 83308 Trostberg Germany

www.alzchem.com

Alzchem Group AG raises EBITDA forecast into the range of EUR 80 million for fiscal year 2023 despite slightly lower sales expectation

Sabine Sieber

Head of Investor Relations & Communications

T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com

Trostberg, October 18, 2023 – Alzchem Group AG is significantly raising its earnings forecast for the full year 2023 despite a slightly lower sales expectation. Group EBITDA is expected to grow to

approximately EUR 80 million (original forecast: up to EUR 70 million). Group sales are expected to be at or slightly below the previous year's level of EUR 542.2 million; this is slightly below the most recent forecast.

The higher earnings forecast is based primarily on the very positive development of the high-margin specialty chemicals business. Particularly noteworthy in this respect are the products from the Human Nutrition (Creapure®) and Animal Nutrition (Creamino®) businesses, as well as the guanidine salts (nitroguanidine).

The forecasts for fiscal year 2023 made in the consolidated financial statements as of 31 December 2022 and last specified in July 2023 are therefore adjusted overall as follows:

	2022	Original forecast 2023 (according to last specification)	Adjusted forecast 2023
Group sales	EUR 542.2 million	Slightly growing	At previous year's level or slightly below
Adjusted EBITDA	EUR 61.4 million	Up to EUR 70 million	Strongly growing to approx. EUR 80 million
Adjusted EBITDA margin*	11.3%	Up to 12%	Noticeably growing
Inventories	EUR 122.4 million	Stable	Slightly to significantly decreasing
Inventory intensity (previously inventory ratio)	22.6%	Stable	Slightly to significantly decreasing
Equity ratio	34.5%	Noticeably growing	Significantly growing

^{*} No adjustments were made.